Clinical Outcomes of Comparison Between Type III Coronary Artery Perforation (CAP) and non-CAP Acute Coronary Syndrome Patients During 3-Year Follow-up.
Autor: | Yildiz, Bekir S., Gunduz, Ramazan, Ozgur, Su, Cizgici, Ahmet Y., Ozdemir, Ibrahim H. |
---|---|
Předmět: |
MYOCARDIAL infarction risk factors
HEMORRHAGE risk factors CORONARY artery injuries THROMBOSIS risk factors RISK assessment HOSPITAL mortality TREATMENT effectiveness RETROSPECTIVE studies DESCRIPTIVE statistics SURGICAL stents ACUTE coronary syndrome LOG-rank test CORONARY artery bypass PERCUTANEOUS coronary intervention CASE-control method RESEARCH CONFIDENCE intervals TIME PATIENT aftercare EVALUATION |
Zdroj: | Angiology; Jan2025, Vol. 76 Issue 1, p58-68, 11p |
Abstrakt: | Coronary artery perforation (CAP) is a potentially fatal complication of percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). This study aimed to investigate in-hospital, 1-year, and 3-year clinical outcomes of type III CAP during PCI in patients with ACS. The study retrospectively evaluated 118 patients with CAP and 43,226 case-control patients. Clinical, angiographic, and procedural characteristics, management, and outcomes were analyzed retrospectively at 1-year and 3-year follow-ups. The mean age of the patients was 66.5 ± 11.9 years (61.8% males). There was no significant difference in hospital mortality between the type III CAP and non-CAP groups. The all-cause mortality was 33.3% in the CAP group vs 1.8% in the non-CAP group at 1 year, and 28.3% in CAP group vs 6.9% in non-CAP group at 3 years (p =.001 for both comparisons). The procedural, clinical, and 1 and 3-year outcomes of type III CAP showed a relatively high risk of myocardial infarction, coronary artery bypass graft, cerebrovascular event, stent thrombosis, and major bleeding at the 1 and 3-year follow-ups. In addition, non-CAP ACS patients had better survival (log-rank: p <.001, 34.29 months 95% Confidence Interval [33.58–35.00]) than type III CAP ACS patients (29.53 months 95% Confidence Interval [27.28–31.78]) at the 3-year follow-up visit. [ABSTRACT FROM AUTHOR] |
Databáze: | Complementary Index |
Externí odkaz: |